Sudip Bandyopadhyay of Inditrade Capital discusses the positive outlook for the Indian pharma sector following the easing of tariff concerns. He highlights Sun Pharma’s promising developments and Glenmark’s landmark R&D deal. Bandyopadhyay also notes the expected price hike in the steel industry due to increased global demand, while emphasizing company-specific uncertainties like JSW Steel’s Bhushan Steel strategy.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets